Navirel (Vinorelbine)

Vinorelbine is a chemotherapy agent that interferes with cell division and is used in the management of solid tumours, especially within the lung and breast cancer treatment pathways.

• Non‑small cell lung cancer: used as first‑line or second‑line therapy to reduce tumour burden and improve progression‑free survival.
• Metastatic breast cancer: employed after anthracycline failure to achieve disease control and prolong survival.
• Malignant pleural effusion associated with lung cancer: administered intrapleurally to alleviate fluid accumulation and improve respiratory comfort.

• Vinorelbine binds to tubulin, inhibiting microtubule polymerisation and preventing formation of the mitotic spindle. This disruption arrests cells in the M phase of the cell cycle, leading to apoptosis of rapidly dividing cancer cells while sparing most non‑dividing normal tissues.

Vinorelbine may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects

• Neutropenia: reduced white blood cell count increasing infection risk.
• Nausea and vomiting: gastrointestinal upset commonly reported.
• Fatigue: persistent tiredness affecting daily activities.
• Alopecia: hair loss that may be temporary.
• Constipation: reduced bowel movements.
• Mild peripheral neuropathy: tingling or numbness in extremities.

Serious or Rare Side Effects

• Febrile neutropenia: fever with low neutrophils requiring urgent care.
• Severe pulmonary toxicity: dyspnoea or interstitial pneumonitis.
• Anaphylactic reactions: sudden severe allergic response.
• Cardiac dysfunction: reduced ejection fraction or arrhythmias.
• Severe peripheral neuropathy: persistent loss of sensation.
• Thrombocytopenia: low platelet count leading to bleeding.

Before initiating Vinorelbine therapy, several safety considerations should be observed.

• Monitor blood counts: perform regular CBC to detect neutropenia and thrombocytopenia.
• Assess liver function: adjust dosing in hepatic impairment.
• Evaluate renal function: use caution in severe renal insufficiency.
• Check for hypersensitivity: discontinue if severe allergic reaction occurs.
• Pregnancy and lactation: avoid unless benefits outweigh potential fetal or infant risk.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Vinorelbine can interact with other medicines, altering its efficacy or toxicity.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase vinorelbine plasma levels.
• Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce therapeutic effect.
• Concurrent myelosuppressive agents: heighten risk of severe bone‑marrow suppression.

Moderate Interactions (Monitor Closely)

• Anticoagulants (e.g., warfarin): may enhance bleeding tendency.
• Antiemetics containing CYP3A4 substrates: monitor for altered metabolism.
• Diuretics: watch for electrolyte disturbances that could exacerbate toxicity.